RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma

ABSTRACT: RE-MIND2 (NCT04697160) compared patient outcomes from the L-MIND (NCT02399085) trial of tafasitamab+lenalidomide with those of patients treated with other therapies for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are autologous stem cell transplant ineligible. We pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Nowakowski, Grzegorz S., Yoon, Dok Hyun, Mondello, Patrizia, Joffe, Erel, Peters, Anthea, Fleury, Isabelle, Greil, Richard, Ku, Matthew, Marks, Reinhard, Kim, Kibum, Zinzani, Pier Luigi, Trotman, Judith, Sabatelli, Lorenzo, Waltl, Eva E., Winderlich, Mark, Sporchia, Andrea, Kurukulasuriya, Nuwan C., Cordoba, Raul, Hess, Georg, Salles, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261238/
https://www.ncbi.nlm.nih.gov/pubmed/37171597
http://dx.doi.org/10.1007/s00277-023-05196-4

Ejemplares similares

Ejemplares similares